Drug Profile

AZD 9838

Alternative Names: AZD-9838

Latest Information Update: 19 Feb 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator AstraZeneca
Class COVID-19 vaccines; RNA vaccines; Virus-like particle vaccines
Mechanism of Action Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Discontinued COVID 2019 infections

Most Recent Events

31 Dec 2025 Discontinued - Phase-I for COVID-2019 infections (Prevention) in USA (IM) before December 2025 (AstraZeneca pipeline, February 2026)
31 Dec 2025 AstraZeneca terminates its phase I ARTEMIS-C trial in Covid-2019 infections (Prevention) in USA (IM) due to strategic portfolio prioritisation (NCT06147063)
27 Mar 2025 AstraZeneca completes the phase I ARTEMIS-C trial in Covid-2019 infections (Prevention) in USA (IM) (NCT06147063)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com